Clinical trials: Nonalcoholic Steatohepatitis
Nonalcoholic Fatty Liver Disease
Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout
Nonalcoholic fatty liver disease (NAFLD) is the most common and harmful chronic liver disease. NAFLD accounts for 49.3% of the total number of chronic liver disease patients in China.
- Trial name
- NCT04772352
- Testing
- febuxostat treatment, lifestyle intervention
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Ningbo No. 1 Hospital
Nonalcoholic Steatohepatitis
Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis
The purpose of this study is to evaluate the effects of solithromycin on hepatic histology and biomarkers in patients with nonalcoholic steatohepatitis.
- Trial name
- NCT02510599
- Testing
- solithromycin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Melinta Therapeutics, Inc.
the Effect of NAFLD on CHB
A Prospective/Retrospective, Observational Follow-up Study of Chronic Hepatitis B With Non-alcoholic Fatty Liver Disease.
This is a prospective/retrospective, observational follow-up study of effects of fatty liver on chronic hepatitis B. Patients will join this study who undergo transient elastography with liver stiffness (LS) and CAP measurements…
- Trial name
- NCT05255978
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Qin Ning
Obesity
South Danish Obesity Initiative, Screening for Unrecognized Obesity Related Disease
People with BMI >30 kg/m2 will be included in at population-based cohort. Additionally, one control group with BMI 18.5-25 kg/m2 and one control group with BMI 25-30 kg/m2 will be included.
- Trial name
- SDOI (NCT05176132)
- Testing
- Life style intervention (dietician+ physiotherapist), Self management, No intervention
- Where
- Denmark
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Claus Bogh Juhl
Nonalcoholic Steatohepatitis
First-in-Human Study of SRT-015 in Healthy Subjects.
This is phase 1 first-in-human trial evaluating SRT-015 to assess safety, tolerability and pharmacokinetics. This study will be conducted in 3 parts - SAD, MAD and Food Effect with target of 96 healthy volunteers.
- Trial name
- NCT04887038
- Testing
- SRT-015
- Where
- Australia
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Syneos Health
Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Dairy Protien Rich Diet for NAFLD Patients
The overarching aim of this project is to investigate effects of dietary interventions on nonalcoholic fatty liver disease (NAFLD) severity and to delineate the relationship with improvements in metabolic aberrations in liver…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome, Caseins, Whey
- Trial name
- DAIPRO-NAFLD (NCT04841915)
- Testing
- High-Protein Diet, Clinical dietician, Weight loss
- Where
- 2 sites in Denmark
- Volunteers
- 46 people
- Sponsor
- University of Aarhus
Non-alcoholic Fatty Liver Disease
Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children
The aim of this study is to evaluate efficacy of fish oil (EPA/DHA) in children with non-alcoholic fatty liver disease.
- Trial name
- NCT01547910
- Testing
- Fish Oil
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Piotr Socha
Nonalcoholic Fatty Liver Disease, Liver Steatosis
Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis
Nowadays, the morbidity of Nonalcoholic fatty liver disease (NAFLD) show ascending trend year by year, which has become an important public health problem in China.
- Conditions
- Nonalcoholic Fatty Liver Disease, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT03386890
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Friendship Hospital
Metabolic-associated Fatty Liver Disease (MAFLD)
Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial
Metabolic-associated fatty liver disease (MAFLD) is a chronic progressive liver disease caused by nutrient excess and insulin resistance (IR) in genetically susceptible individuals.
- Trial name
- NCT06798948
- Testing
- Combination of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Li Lab,MD
Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease
Identification of Liver Fibrosis Biomarkers
Chronic liver disease (CLD) is a major cause of global mortality and morbidity . CLD patients are at an increased risk of developing liver fibrosis (formation of scar tissue), cirrhosis and liver failure and are at significant…
- Conditions
- Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
- Trial name
- NCT06819917
- Testing
- Identification of liver fibrosis biomarkers
- Where
- 2 sites in Denmark, Germany
- Volunteers
- 575 people
- Sponsor
- Roche Diagnostics GmbH
NAFLD, NASH - Nonalcoholic Steatohepatitis
Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver Disease
The purpose of this study is to prospectively evaluate the utility of Liver Incytes in assessing NAFLD with or without advanced fibrosis in patients seen in liver clinics for suspected NAFLD diagnosis.
- Trial name
- NCT04576923
- Testing
- Velacur by Sonic Incytes
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Indiana University
Non-alcoholic Fatty Liver Disease
Adiponectin and Circulating Macrophage Phenotypes in Non-alcoholic Fatty Liver Disease (NAFLD)
In peripheral blood; monocytes and macrophages are found in two phenotype; proinflammatory M1 and anti-inflammatory M2 phenotypes.
- Trial name
- NCT01472120
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Gulhane School of Medicine
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called metabolic dysfunction-associated steatohepatitis (MASH).
- Trial name
- NCT07854782
- Testing
- ALN-CIDEB
- Where
- 4 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Regeneron Pharmaceuticals
Steatohepatitis
A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4
The main aim of this study is to evaluate the safety and tolerability of ontamalimab in participants with a liver disease called nonalcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH) with…
- Trial name
- NCT07052682
- Testing
- Ontamalimab
- Where
- 15 sites in United States
- Volunteers
- 11 people
- Sponsor
- Takeda
Liver Steatoses, Liver Metastasis Colon Cancer
Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis
Non-alcoholic fatty liver disease is becoming increasingly common in Canada and throughout the world. Fatty liver can increase the risks of perioperative complications for those who need liver surgery.
- Conditions
- Liver Steatoses, Liver Metastasis Colon Cancer, NAFLD
- Trial name
- NCT05884723
- Testing
- Ketogenic Diet
- Where
- Canada
- Volunteers
- 124 people
- Sponsor
- Anton Skaro
Non-alcoholic Fatty Liver Disease, Metabolic Syndrome
Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk
The purpose of this study is to learn more about how the body stores fat in and around organs (for example in the liver) and why this affects some people's health more than others.
- Conditions
- Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Metabolically Abnormal Obesity, Metabolically Normal Obesity
- Trial name
- NCT01104220
- Testing
- Weight loss
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Nonalcoholic Fatty Liver Disease
Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease
The purpose of this study is to evaluate the effects and safety of pioglitazone and berberine on the basis of lifestyle intervention to non-alcoholic fatty liver disease patients with impaired glucose regulation or type 2…
- Trial name
- NCT00633282
- Testing
- Life style intervention, pioglitazone, berberine
- Where
- 3 sites in China
- Volunteers
- 184 people
- Sponsor
- Xin Gao
Morbid Obesity, Type2diabetes
Comorbidities Resolution After MGB Surgery and Change in Body Composition
This observational study aims to learn about the correlation between the improving comorbidities associated with obesity after MGB (Mini-Gastric Bypass) surgery and changes in body composition in morbidly obese patients.
- Conditions
- Morbid Obesity, Type2diabetes, Sleep Apnea, Hypothyroidism
- Trial name
- MOGAMBO (NCT06015620)
- Testing
- Mini gastric bypass surgery
- Where
- India
- Volunteers
- 35 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Dyslipidemia, Diabetes
Meta-analyses of Fructose and Cardiometabolic Risk
Diabetes and heart associations continue to discourage high intakes of dietary fructose, a constituent part of the sucrose molecule that is found in fruits and vegetables as a natural sugar and in some processed foods and…
- Conditions
- Dyslipidemia, Diabetes, Prediabetes, Dysglycemia
- Trial name
- NCT01363791
- Testing
- Dietary fructose
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- John Sievenpiper
Fatty Liver Disease
The Role of Sugars in Fat Accumulation in the Liver
This interventional study has 2 parts. In the part A of the project, we will determine how the acute changes in hepatic fat content (HFC) after high-fat load (150 g of fat) are affected by co-administration with three doses of…
- Trial name
- FROGLOSA (NCT06751862)
- Testing
- 150g of fat with glucose, 150g of fat with fructose, 150g of fat with sucrose
- Where
- Czechia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Institute for Clinical and Experimental Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.